HC Wainwright Reiterates "Buy" Rating for TScan Therapeutics (NASDAQ:TCRX)

TScan Therapeutics (NASDAQ:TCRX - Get Free Report)'s stock had its "buy" rating reissued by analysts at HC Wainwright in a note issued to investors on Thursday,Benzinga reports. They presently have a $15.00 price objective on the stock. HC Wainwright also issued estimates for TScan Therapeutics' FY2029 earnings at $0.44 EPS.

A number of other analysts have also weighed in on the stock. Wedbush reaffirmed an "outperform" rating and issued a $7.00 price target on shares of TScan Therapeutics in a research note on Wednesday, March 5th. Needham & Company LLC decreased their price target on shares of TScan Therapeutics from $11.00 to $9.00 and set a "buy" rating on the stock in a research report on Wednesday, March 5th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $9.20.

TScan Therapeutics Stock Performance

Shares of TCRX stock traded down $0.12 on Thursday, hitting $1.86. 407,161 shares of the stock traded hands, compared to its average volume of 312,462. The company has a market capitalization of $99.27 million, a PE ratio of -1.75 and a beta of 0.91. The company's fifty day moving average is $2.41 and its 200 day moving average is $3.99. The company has a debt-to-equity ratio of 0.13, a current ratio of 9.56 and a quick ratio of 9.56. TScan Therapeutics has a 1-year low of $1.79 and a 1-year high of $9.69.

Remove Ads

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last posted its earnings results on Wednesday, March 5th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.02). The company had revenue of $0.67 million for the quarter, compared to the consensus estimate of $1.43 million. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. On average, equities research analysts predict that TScan Therapeutics will post -1.12 earnings per share for the current fiscal year.

Institutional Trading of TScan Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Lynx1 Capital Management LP lifted its holdings in shares of TScan Therapeutics by 2.5% during the 4th quarter. Lynx1 Capital Management LP now owns 5,357,347 shares of the company's stock worth $16,286,000 after acquiring an additional 132,747 shares during the period. Great Point Partners LLC increased its stake in shares of TScan Therapeutics by 8.0% in the 3rd quarter. Great Point Partners LLC now owns 1,016,375 shares of the company's stock valued at $5,062,000 after buying an additional 75,544 shares during the period. Geode Capital Management LLC raised its stake in shares of TScan Therapeutics by 8.1% during the third quarter. Geode Capital Management LLC now owns 973,466 shares of the company's stock worth $4,849,000 after buying an additional 72,967 shares during the last quarter. abrdn plc grew its stake in shares of TScan Therapeutics by 137.8% during the fourth quarter. abrdn plc now owns 883,704 shares of the company's stock worth $2,686,000 after purchasing an additional 512,049 shares during the period. Finally, Checkpoint Capital L.P. bought a new position in TScan Therapeutics during the third quarter worth about $4,110,000. Institutional investors and hedge funds own 82.83% of the company's stock.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.